Stockwatch: Uncertainty Trumps Earnings Seasons Fundamentals
Executive Summary
A post-US election relief rally was magnified in life science stocks last week and swept away poor third-quarter earnings results at Valeant, Endo, AstraZeneca and Impax.
You may also be interested in...
Valeant Is Weighing Offers For Assets As Stocks Plunges Again
CEO Joseph Papa confirmed the company is in discussions regarding the sale of its gastrointestinal business, but insisted the company does not need to divest assets to maintain liquidity.
Stockwatch: Landscaping Earnings Announcements At Valeant And Endo
Endo, Valeant, Mylan and Perrigo all reported second-quarter results last week. Only maintenance of full-year guidance was needed for stock price outperformance but guidance cuts for all look like just a matter of time.
Teva Embarks On New Phase With FTC Clearance Of Allergan Generics
Teva said the deal will close the first week of August, after agreeing to sell assets related to 79 pharmaceutical products to gain FTC clearance.